MedImpact names Rebekah Gregg Senior Vice President of Marketing and Digital Solutions. Pharmacy benefits executive will help the company communicate its affordability, technology, and clinical solutions to a healthcare industry undergoing change SAN DIEGO, CA - September 24, 2026 - MedImpact, the nation's largest independent pharmacy benefit and health solutions company, has named Rebekah Gregg Senior Vice President of Marketing and Digital Solutions. Gregg joins as MedImpact brings to market new solutions that give healthcare payers greater visibility, choices, and control over pharmacy benefits and lower costs for both members and plans. "Rebekah has spent much of her career working closely with payers and knows what challenges our clients face, what they need, and how to communicate it clearly," said MedImpact Executive Vice President Zach Johnson. "Her timing is excellent. We have exciting work underway and she is the right person to help us bring new solutions to the market." Payers today are facing rising drug prices, new therapies with historically high price tags, changing regulatory and marketplace dynamics, and an affordability crisis for members at the counter. An independent company for nearly 40 years, MedImpact is taking bold action by re-engineering the drug supply chain and rolling out new technologies, formularies, models, and clinical programs. Rebekah's expertise will be critical in communicating the value of the company's innovative solutions to the marketplace. Gregg joins MedImpact from Pharmaceutical Strategies Group (PSG), an EPIC company, where she served as Chief Operating Officer. In that role, she oversaw marketing, research, and operations, and an analytics platform that was used by payers covering more than 16 million members. She also led the firm's research and satisfaction studies, giving her a close view of what plan sponsors look for in pharmacy benefit partners. Keep up to date on the latest in the industry. Press Releases Claria transforms PBM economics by giving plan sponsors the transparency, control, and predictability they need to maximize their investment in medications Press Releases HCG X program provides payers 80.6% PMPQ savings and a 5:1 ROI in year one Press Releases Leveraging supply chain innovation and award-winning lifestyle management program, new solutions deliver lower costs, improved clinical care, and greater member access Press Releases By re-engineering the drug supply chain and formularies, Patel and the MedImpact team are increasing transparency, predictability and affordability

How payers are rethinking specialty drug benefits | Asembia AXS26 Summit. There have been tremendous advances in specialty drugs, but those advances have also brought a lot of complexity for payers. Payers are considering new strategies for their specialty benefit. How payers are managing and covering specialty drug benefits is evolving, say leaders from Pharmaceutical Strategies Group (PSG), who presented today highlights from PSG's 2026 Trends in Specialty Drug Benefits at Asembia's 2026 Specialty Pharmacy Summit, being held in Las Vegas from April 26 to April 30. PSG's research found that payers are placing more attention on specialty drugs covered under the medical benefit, showing greater willingness to accept fewer rebates in exchange for stronger utilization management controls, and re-evaluating whether current PBM management models are aligned with their best interests. The growing number of specialty drugs and expanded indications for existing drugs is also creating substantial operational complexity for payers across both pharmacy and medical benefits. Payers' ratings place developing and implementing effective coverage strategies for new drugs and expanded indications as their top challenge, surpassing access to integrated data and affordability for members. In an interview ahead of the meeting, Renee Rayburg, R.Ph., VP of clinical strategy at PSG, and Morgan Lee, Ph.D., VP of research and marketing at PSG, discussed some of the findings from the survey and the evolving landscape of specialty drug benefits, as well as current trends and future projections in specialty drug benefit design. Below is an excerpt from its conversation. Q: What are some of the challenges payers face concerning specialty pharmacy? Rayburg: Payers are challenged with the specialty drug pipeline, expanded indication pipeline, and new products that have been approved. New this year in the survey was an option for respondents to rank their challenges. The strategy for covering expanded indications and specialty drugs has become really important because specialty drugs have dominated new drug approvals. Over the last 10 years, specialty drugs have been at least 50% of new drug approvals, the novel new drug approvals that are from the FDA. But in 2025, specialty drugs reached a high of 76% of the novel drugs that were approved. Specialty drugs are very high cost, based on some of its other reports, with an average of a $5,000 monthly cost per claim. Specialty is going to continue to increase in double-digit trends for its clients. The science continues to advance. There are a lot of drugs in the pipeline, new and expanded indications for existing drugs. Dupixent, for example, was approved in 2017 for atopic dermatitis; it now has nine indications including for asthma. As a pharmacist, I find the science exciting. Lee: These advances are incredible, and they are also putting a tremendous amount of pressure on payers as they work on how to create a sustainable strategy. That's the beauty and the challenge of where Managed Healthcare Executive is at right now. There are a tremendous number of advances, but that's also brought a lot of complexity to the space. What Managed Healthcare Executive is seeing payers do is really having to look at new strategies and different ways that they might think about their specialty benefit because of these changes. Question: How are players structuring their benefits in terms of utilization management, including prior authorization? Lee: In terms of prior authorization, Managed Healthcare Executive has been talking about the topic for a really long time, but this is its first year of asking a question more specific to whether payers are supportive of changes that would include reducing or removing prior authorization for some therapeutic classes. Managed Healthcare Executive found that they are also not supportive of just wholesale removal, and they recognize that prior authorization can provide value to them in some areas. Another new question Managed Healthcare Executive asked this year was about their level of concern around unintended consequences of utilization management such as prior authorization, step therapy, and other types of strategies. Managed Healthcare Executive looked at it by disease category. In oncology and multiple sclerosis, for example, there were much higher levels of concern about what impact UM might have compared with atopic dermatitis, where they were less concerned. Rayburg: The process of prior authorization is not perfect. I would even say it's probably a little bit broken, but it doesn't appear from the survey respondents that people are ready to just do away with it. Managed Healthcare Executive didn't ask about AI and prior authorization but there are vendors today that are trying to use AI to comb through the data and trying to also use AI or forms of it to make it easier to consolidate the data. AI can be a good tool that maybe could collect the electronic health record or notes from the charts and then diagnosis codes. There are companies that are doing that and looking into what the other information that supports the PA and the PA process is. Managed Healthcare Executive made an intentional decision to leave it out of this survey, because in a survey, it is very hard to establish what is truly meant when someone says they're using the AI-enhanced tools. Question: This is the first year your survey looked at the role of the specialty pharmacy. What did you find? Lee: There's a lot of good conversation happening right now around the role of specialty pharmacies about what they are providing and their essential role. Managed Healthcare Executive wanted to look into whether payers are perceiving that some specialty pharmacies are different from others in terms of the way they're supporting patients. There's some differentiation perceived, but maybe not to the degree that some specialty pharmacies might have expected. About one in three of the health plans in its survey gave a rating on specialty pharmacies that leaned toward not seeing much differentiation there. It was a bit surprising. Rayburg: Payers in general have higher expectations from specialty pharmacies when it comes to clinical expertise and the enhanced patient care. They're not seeing differences between them. It's important to have awareness about this because specialty pharmacies may not be aware that they're being seen in that light. Get the latest industry news, event updates, and more from Managed healthcare Executive.